Is faster safer? Cluster versus short conventional subcutaneous allergen immunotherapy.

abstract：:Aim: To evaluate the long-term efficacy of sublingual immunotherapy (SLIT) in treating mite-sensitized allergic rhinitis (AR). Materials & methods: 150 AR children were randomly divided into SLIT and pharmacotherapy (PT) groups, receiving a 3-year course of SLIT along with PT or PT only. Results: The symptom and medic...

journal_title：Immunotherapy

authors： Chen WB,Shen XF,Li Q,Zhou WC,Cheng L

更新日期：2020-08-01 00:00:00

abstract：AIM:There is still no specific therapy for infection with the highly pathogenic avian influenza A virus (HPAI) H5N1, which caused 39 human cases with a 64% fatality rate in 2013. MATERIALS & METHODS:We prepared highly purified specific equine polyclonal immunoglobulin fragments (F(ab')2) against H5N1 and tested them f...

journal_title：Immunotherapy

authors： Herbreteau CH,Jacquot F,Rith S,Vacher L,Nguyen L,Carbonnelle C,Lotteau V,Jolivet M,Raoul H,Buchy P,Saluzzo JF

更新日期：2014-01-01 00:00:00

abstract：AIMS:A therapeutic vaccine based on monocyte-derived dendritic cells (MDDCs) has been shown to represent a promising strategy for the treatment of cancer and viral infections. Here, we characterized the MDDCs used as an immunogen in a clinical trial for an anti-HIV-1 therapeutic vaccine. PATIENTS & METHODS:Monocytes o...

journal_title：Immunotherapy

authors： da Silva LT,da Silva WC,de Almeida A,da Silva Reis D,Santillo BT,Rigato PO,da Silva Duarte AJ,Oshiro TM

更新日期：2018-08-01 00:00:00

abstract：:The era of active immunotherapy has now been successfully ushered into the clinical realm of advanced prostate cancer. The successful clinical trial development and US FDA approval of sipuleucel-T (Provenge®) has revamped the therapeutic paradigm for advanced prostate cancer. Nonetheless, physician and patient educati...

journal_title：Immunotherapy

authors： Shore ND

更新日期：2011-08-01 00:00:00

abstract：:Increasing evidence indicates the importance of human natural killer (NK) cells in the immune response against certain viral infections. In the present article, we summarize information on NK cell responses against several viruses and on the nature of NK cell receptor-ligand interactions involved in these responses. R...

journal_title：Immunotherapy

authors： Marcenaro E,Carlomagno S,Pesce S,Della Chiesa M,Parolini S,Moretta A,Sivori S

更新日期：2011-09-01 00:00:00

abstract：:In recent years, nanoparticulate-mediated drug delivery research has examined a full spectrum of nanoparticles that can be used in diagnostic and therapeutic cancer applications. A key aspect of this technology is in the potential to specifically target the nanoparticles to diseased cells using a range of molecules, i...

journal_title：Immunotherapy

authors： Fay F,Scott CJ

更新日期：2011-03-01 00:00:00

abstract：:NKT cells are a heterogeneous subset of specialized, self-reactive T cells, with innate and adaptive immune properties, which allow them to bridge innate and adaptive immunity and profoundly influence autoimmune and malignant disease outcomes. NKT cells mediate these activities through their ability to rapidly express...

journal_title：Immunotherapy

authors： Subleski JJ,Jiang Q,Weiss JM,Wiltrout RH

更新日期：2011-10-01 00:00:00

abstract：AIM:This meta-analysis aims at assessing the correlation of PD-L1 levels and response PD-1/PD-L1 inhibitors in advanced malignant melanoma. METHODS:Eligible studies included those evaluating PD-1/PD-L1 inhibitors in advanced melanoma and correlating the outcomes to PD-L1 levels. RESULTS:After preclusion of ineligible...

journal_title：Immunotherapy

authors： Abdel-Rahman O

更新日期：2016-09-01 00:00:00

abstract：:Aim: To analyze the efficacy of checkpoint inhibitors in soft tissue sarcoma. Materials & methods: We retrospectively reviewed patients with advanced soft tissue sarcoma treated with ipilimumab and nivolumab. All patients who received at least one cycle were included. Results: One patient had a complete response and f...

journal_title：Immunotherapy

authors： Zhou M,Bui N,Bolleddu S,Lohman M,Becker HC,Ganjoo K

更新日期：2020-12-01 00:00:00

abstract：:Immunotherapy of cancer is a rapidly developing field; one such development is the manipulation and use of natural killer (NK) cells. These cells with 'killer instincts' are an attractive cell to utilize, as they are directly reactive toward tumor and could potentially activate the endogenous adaptive immune system. T...

journal_title：Immunotherapy

authors： Pegram HJ,Kershaw MH,Darcy PK

更新日期：2009-07-01 00:00:00

abstract：AIM:It is becoming apparent that emphysema is partly driven by self-reactive T cells inducing inflammatory damage. Thus, T cells become targets for therapy similar to other autoimmune diseases. Costimulatory blockade therapy targets disease-specific T cells, rendering them ineffective by blocking a necessary costimulat...

journal_title：Immunotherapy

authors： Newton AH,Danahy DB,Chan MA,Benedict SH

更新日期：2015-01-01 00:00:00

abstract：:Rituximab is a chimeric monoclonal antibody used to treat hematologic and autoimmune diseases by depleting CD20-expressing B cells. Patients may develop hypogammaglobulinemia following treatment, with some demonstrating failure of B-cell recovery. The true frequency of hypogammaglobulinemia and/or impaired B-cell reco...

journal_title：Immunotherapy

authors： Sacco KA,Abraham RS

更新日期：2018-06-01 00:00:00

abstract：:Brain tumors present unique therapeutic challenges and they include glioblastoma (GBM) and metastases from cancers of other organs. Current treatment options are limited and include surgical resection, radiation therapy, laser interstitial thermal therapy and chemotherapy. Although much research has been done on the d...

journal_title：Immunotherapy

authors： Liu Y,Chongsathidkiet P,Crawford BM,Odion R,Dechant CA,Kemeny HR,Cui X,Maccarini PF,Lascola CD,Fecci PE,Vo-Dinh T

更新日期：2019-10-01 00:00:00

abstract：:HER2/neu is expressed in the majority of in situ breast cancers, but maintained in 20-30% of invasive breast cancer (IBC). During breast tumorigenesis, there is a progressive loss of anti-HER2 CD4(pos) Th1 (anti-HER2Th1) from benign to ductal carcinoma in situ, with almost complete loss in IBC. This anti-HER2Th1 respo...

journal_title：Immunotherapy

authors： De La Cruz LM,Nocera NF,Czerniecki BJ

更新日期：2016-10-01 00:00:00

abstract：:Mycobacterium bovis bacille Calmette-Guerin (BCG) is one of the great success stories of immunotherapy as a treatment for superficial urothelial carcinoma of the bladder. Despite clinical effectiveness in over 50% of patients, the high incidence of local side effects and presence of nonresponders has led to efforts to...

journal_title：Immunotherapy

authors： Kresowik TP,Griffith TS

更新日期：2009-03-01 00:00:00

abstract：:Background: Severe pneumonia and acute respiratory distress syndrome (ARDS) due to COVID-19 is a challenge for nowadays medical practice. Although there is no clarity in the principal mechanism of lung damage and ARDS development, it has been suggested that one of the main reasons of this pathology is the hyperactivat...

journal_title：Immunotherapy

authors： Cala-García JD,Sierra-Bretón JD,Cavelier-Baiz JE,Faccini-Martínez ÁA,Pérez-Díaz CE

更新日期：2020-10-01 00:00:00

abstract：:Monoclonal antibodies remain a primary product option for novel cancer treatment. The properties of an antibody are a function of the antigen specificity and constant region incorporated. The rapid advance in molecular understanding of cancer biology and the host-tumor interaction has defined a new range of targets fo...

journal_title：Immunotherapy

authors： Nicodemus CF

更新日期：2015-01-01 00:00:00

abstract：:Acute pyelonephritis is an infection of the renal parenchyma and renal pelvis. When it is caused by a typical pathogen in an immunocompetent female patient with normal urinary tract, it is considered uncomplicated. In all other cases, sepsis is the most worrisome complication. In the event of sepsis, patients should b...

journal_title：Immunotherapy

authors： Tsaganos T,Giamarellos-Bourboulis EJ

更新日期：2016-01-01 00:00:00

abstract：:Activation of a patient's immune system offers an attractive approach to prevent and treat hepatocellular carcinoma (HCC). However, the antitumor efficacy of current HCC vaccines was weak owing to insufficient immune activation of targeting self/tumor antigens. We recently found that epitope-optimized α-fetoprotein ef...

journal_title：Immunotherapy

authors： He Y,Hong Y,Mizejewski GJ

更新日期：2014-01-01 00:00:00

abstract：:Therapeutic vaccination with dendritic cells (DCs) is recognized as an important experimental therapy for the treatment of minimal residual disease in acute myeloid leukemia. Many sources of leukemia-associated antigens and different methods for antigen loading of DCs have been used in an attempt to optimize anti-tumo...

journal_title：Immunotherapy

authors： van den Ancker W,van Luijn MM,Westers TM,Bontkes HJ,Ruben JM,de Gruijl TD,Ossenkoppele GJ,van de Loosdrecht AA

更新日期：2010-01-01 00:00:00

abstract：:Hereditary angioedema (HAE) is a relatively rare autosomal dominant disorder that is typically characterized by recurrent episodes of edema in various body locations. It is most commonly caused by an inherited deficiency of functionally active C1 esterase inhibitor (C1-INH). Replacement therapy with a human plasma-der...

journal_title：Immunotherapy

authors： Bork K

更新日期：2014-01-01 00:00:00

abstract：:Aim: To assess the safety and effectiveness of an allergen immunotherapy (AIT) with a microcrystalline tyrosine-associated mite allergoid in real-world patients with allergic rhinitis (AR). Materials & methods: Retrospective, multicenter study assessing the safety of AIT in patients aged 5 to 65 years with AR, with or...

journal_title：Immunotherapy

authors： Sala-Cunill A,Pérez-Formoso JL,Torán-Barona C,Almeida-Sánchez ZM,Álvarez-Fernández JA,García-Núñez I,Linana-Santafé JJ,Martínez-Tadeo JA,Boronat-Barado A,Justicia JL

更新日期：2020-09-01 00:00:00

abstract：:Evaluation of: Savoldo B, Ramos CA, Liu E et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121(5), 1822-1826 (2011). Chimeric antigen receptor (CAR)-T cells are promising antitumor immunotherapies. However, there are limit...

journal_title：Immunotherapy

authors： Gandhi M,Jones K

更新日期：2011-12-01 00:00:00

abstract：:Over the last two decades, anti-CD20 monoclonal antibody (mAb) therapy has improved patient outcome in B-cell malignancies, and confirmed CD20 as an important target in chronic lymphocytic leukemia (CLL). Until recently, the gold standard was based on the utilization of rituximab combined with chemotherapy (fludarabin...

journal_title：Immunotherapy

authors： Bagacean C,Zdrenghea M,Tempescul A,Cristea V,Renaudineau Y

更新日期：2016-05-01 00:00:00

abstract：:Mesenchymal stem cells (MSCs) show considerable promise as a cellular immunotherapy for the treatment of a number of autoimmune and inflammatory disorders. However, the precise physiologically and therapeutically relevant mechanism(s) by which MSCs mediate immune modulation remains elusive. Dental pulp stem cells are ...

journal_title：Immunotherapy

authors： Laing AG,Riffo-Vasquez Y,Sharif-Paghaleh E,Lombardi G,Sharpe PT

更新日期：2018-03-01 00:00:00

abstract：:Aim: Previously, we constructed a novel anti-p21Ras single-chain antibody fragment, KGH-R1-single-chain fragment variant (ScFv). However, the immunoreactivity of this antibody toward p21Ras is still unclear. Materials & methods: ELISAs, immunohistochemistry, western blotting and immunofluorescence were used to identif...

journal_title：Immunotherapy

authors： Wang P,Pan X,Feng Q,Zou H,Cui J,He Y,Luo Y,Yang J

更新日期：2020-08-01 00:00:00

abstract：:FOCIS goes South: Advances in Translational and Clinical Immunology was the first Federation of Clinical Immunology Societies (FOCIS) ( www.focisnet.org ) meeting held in Latin America (May 15-17, 2017, Santiago de Chile, Chile). The meeting was organized as a 3-day workshop and was fostered by the Millennium Institut...

journal_title：Immunotherapy

authors： Kalergis AM,Anegon I,González PA

更新日期：2017-09-01 00:00:00

abstract：:Meningiomas are increasingly appreciated to share similar features with other intra-axial central nervous system neoplasms as well as systemic cancers. Immune checkpoint inhibition has emerged as a promising therapy in a number of cancers, with durable responses of years in a subset of patients. Several lines of evide...

journal_title：Immunotherapy

authors： Bi WL,Wu WW,Santagata S,Reardon DA,Dunn IF

更新日期：2016-06-01 00:00:00

abstract：:Chronic rhinosinusitis with nasal polyposis (CRSwNP) imparts a significant healthcare challenge, resulting in diminished quality of life for patients and high costs with resource utilization for disease management. Understanding of CRSwNP pathophysiology has progressively evolved and the identification of various infl...

journal_title：Immunotherapy

authors： Boyle JV,Lam K,Han JK

更新日期：2020-02-01 00:00:00

abstract：:The dysfunctional immune response that characterizes systemic lupus erythematosus (SLE) associates with an unbalanced production of soluble mediators that are crucial in promoting and sustaining chronic inflammation. The successful use of biologics in several autoimmune diseases has led to studies in SLE aimed at cont...

journal_title：Immunotherapy

authors： La Cava A

更新日期：2010-07-01 00:00:00